Payment overview · 2025
General Payments
$476.57
14 reported records · 6 companies
Healthcare provider profile · identity verified
Magued Ibrahim, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · DEBARY, FL · NPI 1407901135
Verified facts
What the public records show
CMS Open Payments records show Magued Ibrahim, M.D. received $476.57 in general payments during 2025 across 14 reported records.
AstraZeneca Pharmaceuticals LP accounted for 72.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $346.08 | 72.6% | 8 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $48.64 | 10.2% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $23.76 | 5.0% | 1 | 2025 |
| REVANCE THERAPEUTICS, INC. | Unresolved — no canonical attribution shown | $22.17 | 4.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.74 | 3.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $17.18 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $476.57 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $331.46 | 7 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $48.64 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $23.76 | 1 | 2025 |
Source payment records
|
|||||
| DAXXIFY Normalized: daxxify |
Drug | REVANCE THERAPEUTICS, INC. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $18.74 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $14.62 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 97 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
97 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 468 | 131 |
| Lisinopril | Lisinopril | 443 | 120 |
| Atorvastatin Calcium | Atorvastatin Calcium | 413 | 119 |
| Simvastatin | Simvastatin | 324 | 87 |
| Levothyroxine Sodium | Levothyroxine Sodium | 321 | 78 |
| Losartan Potassium | Losartan Potassium | 285 | 84 |
| Pantoprazole Sodium | Pantoprazole Sodium | 266 | 86 |
| Gabapentin | Gabapentin | 246 | 71 |
| Furosemide | Furosemide | 239 | 79 |
| Metformin Hcl | Metformin Hcl | 225 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 217 | 68 |
| Metoprolol Tartrate | Metoprolol Tartrate | 205 | 60 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 202 | 58 |
| Meloxicam | Meloxicam | 182 | 67 |
| Omeprazole | Omeprazole | 162 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 150 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 45 |
| Clonazepam | Clonazepam | 138 | 26 |
| Alprazolam | Alprazolam | 133 | 19 |
| Temazepam | Temazepam | 128 | 25 |
| Trazodone Hcl | Trazodone Hcl | 125 | 43 |
| Pioglitazone Hcl | Pioglitazone Hcl | 120 | 34 |
| Sertraline Hcl | Sertraline Hcl | 111 | 34 |
| Fluticasone Propionate | Fluticasone Propionate | 108 | 28 |
| Eliquis | Apixaban | 107 | 27 |
| Lovastatin | Lovastatin | 107 | 31 |
| Azithromycin | Azithromycin | 103 | 76 |
| Glipizide | Glipizide | 97 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 97 | 19 |
| Carvedilol | Carvedilol | 94 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 93 | 24 |
| Prednisone | Prednisone | 93 | 57 |
| Alendronate Sodium | Alendronate Sodium | 92 | 27 |
| Allopurinol | Allopurinol | 91 | 27 |
| Finasteride | Finasteride | 91 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 90 | 26 |
| Baclofen | Baclofen | 84 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 83 | 22 |
| Montelukast Sodium | Montelukast Sodium | 80 | 23 |
| Hydralazine Hcl | Hydralazine Hcl | 77 | 16 |
| Meclizine Hcl | Meclizine Hcl | 77 | 26 |
| Pregabalin | Pregabalin | 73 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 70 | 21 |
| Ibuprofen | Ibuprofen | 68 | 27 |
| Donepezil Hcl | Donepezil Hcl | 65 | 22 |
| Famotidine | Famotidine | 63 | 22 |
| Buspirone Hcl | Buspirone Hcl | 61 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 19 |
| Celecoxib | Celecoxib | 56 | 17 |
| Warfarin Sodium | Warfarin Sodium | 54 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 51 | 18 |
| Ozempic | Semaglutide | 50 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 48 | 43 |
| Duloxetine Hcl | Duloxetine Hcl | 47 | 11 |
| Lorazepam | Lorazepam | 47 | 16 |
| Potassium Chloride | Potassium Chloride | 46 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 33 |
| Atenolol | Atenolol | 41 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 41 | 17 |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 14 |
| Ketoconazole | Ketoconazole | 40 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | 12 |
| Januvia | Sitagliptin Phosphate | 38 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 38 | 13 |
| Ezetimibe | Ezetimibe | 36 | 12 |
| Propranolol Hcl | Propranolol Hcl | 36 | 12 |
| Tramadol Hcl | Tramadol Hcl | 35 | 13 |
| Naproxen | Naproxen | 34 | suppressed |
| Lamotrigine | Lamotrigine | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | suppressed |
| Nitroglycerin | Nitroglycerin | 30 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 30 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 28 | 12 |
| Jardiance | Empagliflozin | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 16 |
| Mirtazapine | Mirtazapine | 27 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | 23 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Trulicity | Dulaglutide | 24 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Nystatin | Nystatin | 22 | suppressed |
| Bumetanide | Bumetanide | 21 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 21 | 16 |
| Digoxin | Digoxin | 21 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 19 | suppressed |
| Ibu | Ibuprofen | 19 | suppressed |
| Memantine Hcl | Memantine Hcl | 19 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Topiramate | Topiramate | 19 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 16 | 12 |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Azelastine Hcl | Azelastine Hcl | 15 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Trimethoprim | Trimethoprim | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Entresto | Sacubitril/Valsartan | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Amoxicillin | Amoxicillin | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Klor-Con M20 | Potassium Chloride | 13 | suppressed |
| Metolazone | Metolazone | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 12 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Diazepam | Diazepam | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Vascepa | Icosapent Ethyl | 12 | suppressed |
| Vraylar | Cariprazine Hcl | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Bupropion Xl | Bupropion Hcl | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Klor-Con 10 | Potassium Chloride | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $476.57 · 14 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Cologuard Collection Kit, DAXXIFY, QULIPTA, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Trelegy Ellipta play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error